• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Rapport Therapeutics Inc.

    10/18/24 5:23:54 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RAPP alert in real time by email
    SC 13G 1 s13g_093024-rapportthera.htm

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G
    (Rule 13d-102)
     
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
    TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED
    PURSUANT TO RULE 13d-2(b)
    (Amendment No.   )1
     
     
    Rapport Therapeutics, Inc.
    (Name of Issuer)
     
    Common Stock, $0.001 par value
    (Title of Class of Securities)
     
    75383L102
    (CUSIP Number)
     
    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [ ] Rule 13d-1(b)

     

    [ ] Rule 13d-1(c)

     

    [X] Rule 13d-1(d)

     

     

     

    1 The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

     

     

     

     
     

     

    CUSIP No. 75383L102 Page 2 of 7

     

     

    1.

    NAME OF REPORTING PERSON

     

    Johnson & Johnson

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)       [ ]

    (b)       [ ]

    3. SEC USE ONLY
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    New Jersey

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5. SOLE VOTING POWER -0-
    6. SHARED VOTING POWER 2,498,051
    7. SOLE DISPOSITIVE POWER -0-
    8. SHARED DISPOSITIVE POWER 2,498,051
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED
    BY EACH REPORTING PERSON

    2,498,051
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 6.8%
    12. TYPE OF REPORTING PERSON CO
             

     

     

     

     
     

     

    CUSIP No. 75383L102 Page 3 of 7

     

     

    1.

    NAME OF REPORTING PERSON

     

    Johnson & Johnson Innovation-JJDC, Inc.

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)       [ ]

    (b)       [ ]

    3. SEC USE ONLY
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5. SOLE VOTING POWER -0-
    6. SHARED VOTING POWER 2,498,051
    7. SOLE DISPOSITIVE POWER -0-
    8. SHARED DISPOSITIVE POWER 2,498,051
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED
    BY EACH REPORTING PERSON

    2,498,051
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 6.8%
    12. TYPE OF REPORTING PERSON CO
             

     

     

     

     
     

     

    CUSIP No. 75383L102 Page 4 of 7

     

     

    SCHEDULE 13G

     

    ITEM 1(a) NAME OF ISSUER:
       
      Rapport Therapeutics, Inc.
       
    ITEM 1(b) ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:
       
      1325 Boylston Street, Suite 401, Boston, MA  02215
       
    ITEM 2(a) NAME OF PERSON FILING:
       
      This statement is being filed by Johnson & Johnson, a New Jersey corporation (“J&J”), and Johnson & Johnson Innovation-JJDC, Inc., a Delaware corporation (“JJDC”).  JJDC is a wholly-owned subsidiary of J&J. The securities reported herein as being held by J&J and JJDC are directly beneficially owned by JJDC.  J&J may be deemed to indirectly beneficially own the securities that are directly beneficially owned by JJDC. The Joint Filing Agreement between J&J and JJDC is attached hereto as Exhibit A.
       
    ITEM 2(b) ADDRESS OF PRINCIPAL BUSINESS OFFICE:
       
     

    J&J: One Johnson & Johnson Plaza, New Brunswick, NJ 08933

    JJDC: 410 George Street, New Brunswick, NJ 08901

       
    ITEM 2(c) CITIZENSHIP:
       
     

    J&J: New Jersey

    JJDC: Delaware

       
    ITEM 2(d) TITLE OF CLASS OF SECURITIES:
       
      Common Stock, $0.001 par value (“Common Stock”)
       
    ITEM 2(e) CUSIP NUMBER:  
       
      75383L102
       

     

     
     

     

    CUSIP No. 75383L102 Page 5 of 7

     

     

    ITEM 3 STATEMENTS FILED PURSUANT TO RULES 13D-1(B) OR 13D-2(B) OR (C):
       
      Not applicable.
       
    ITEM 4 OWNERSHIP:
     

     

    The information requested in this item is incorporated herein by reference to the cover pages to this Schedule 13G.

     

    Percentage ownership is based on 36,576,457 shares of Common Stock outstanding as of August 8, 2024, as reported in the Issuer’s Report on Form 10-Q for the period ended June 30, 2024 filed with the Securities and Exchange Commission on August 8, 2024.

           
    ITEM 5 OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
       
      Not applicable.
       
    ITEM 6 OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
       
      Not applicable.
       
    ITEM 7 IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT COMPANY:
       
      Not applicable.
       
    ITEM 8 IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
       
      Not applicable.
       
    ITEM 9 NOTICE OF DISSOLUTION OF GROUP:
       
      Not applicable.
       
    ITEM 10 CERTIFICATION:
       
      Not applicable.

     

     
     

     

    CUSIP No. 75383L102 Page 6 of 7

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Dated: October 18, 2024

     

     

     

    JOHNSON & JOHNSON

     

      By: /s/ Marc Larkins
      Name: Marc Larkins
      Title: Secretary
         

     

      JOHNSON & JOHNSON INNOVATION-JJDC, INC.
         
      By: /s/ Jill McManus
      Name: Jill McManus
      Title: Assistant Treasurer
         

     

     

     

     
     

     

    CUSIP No. 75383L102 Page 7 of 7

     

     

    EXHIBIT A

     

    JOINT FILING AGREEMENT

     

    The undersigned hereby agree that the statement on Schedule 13G to which this Agreement is annexed as Exhibit A, and any amendments thereto, is and will be filed on behalf of each of them in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

     

    Dated: October 18, 2024

     

     

    JOHNSON & JOHNSON

     

      By: /s/ Marc Larkins
      Name: Marc Larkins
      Title: Secretary
         

     

      JOHNSON & JOHNSON INNOVATION-JJDC, INC.
         
      By: /s/ Jill McManus
      Name: Jill McManus
      Title: Assistant Treasurer
         

     

     

     

     

    Get the next $RAPP alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RAPP

    DatePrice TargetRatingAnalyst
    8/6/2025$31.00Buy
    H.C. Wainwright
    4/8/2025Mkt Outperform
    Citizens JMP
    7/2/2024Buy
    TD Cowen
    7/2/2024$35.00Buy
    Jefferies
    7/2/2024$35.00Buy
    Stifel
    More analyst ratings

    $RAPP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors

    Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Raymond Sanchez, M.D., to its Board of Directors, effective August 12, 2025. Dr. Sanchez is a highly accomplished executive with a strong background in medicine and over 20 years of strategic experience in the life sciences industries. "We are delighted to welcome Ray to our Board of Directors as we continue advancing multiple clinical-stage precision psychiatry programs," said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. "Ray brings an impress

    8/13/25 8:03:00 AM ET
    $ANRO
    $CERE
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update

    RAP-219 Phase 2a trial in patients with drug-resistant focal onset seizures is fully enrolled and on track for topline results in September 2025Phase 2 trial of RAP-219 in bipolar mania has been initiated and is enrolling patients; trial remains on track, with topline results anticipated in the first half of 2027Ended the quarter with $260.4 million in cash, cash equivalents, and short-term investments, excluding restricted cash, which is expected to fund operations through the end of 2026 BOSTON and SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and d

    8/7/25 7:00:00 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates

    BOSTON and SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today will host its inaugural Investor and Analyst Day, featuring presentations from Rapport's executive team on the Company's strategic priorities and updates from its clinical pipeline, including progress on the RAP-219 Phase 2a trial in focal epilepsy. The event's agenda also includes a fireside chat with key opinion leader and professor of Neurology at NYU Langone's Comprehensive Epileps

    6/2/25 2:45:00 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Bredt David sold $127,466 worth of shares (8,500 units at $15.00), decreasing direct ownership by 2% to 426,642 units (SEC Form 4)

    4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

    8/18/25 5:14:19 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Scientific Officer Bredt David sold $118,962 worth of shares (8,500 units at $14.00), decreasing direct ownership by 2% to 435,142 units (SEC Form 4)

    4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

    7/16/25 4:14:04 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Young Wendy B.

    4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

    6/18/25 4:15:26 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Rapport Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Rapport Therapeutics with a rating of Buy and set a new price target of $31.00

    8/6/25 8:02:07 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citizens JMP initiated coverage on Rapport Therapeutics

    Citizens JMP initiated coverage of Rapport Therapeutics with a rating of Mkt Outperform

    4/8/25 9:31:03 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on Rapport Therapeutics

    TD Cowen initiated coverage of Rapport Therapeutics with a rating of Buy

    7/2/24 8:03:15 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPP
    SEC Filings

    View All

    SEC Form 10-Q filed by Rapport Therapeutics Inc.

    10-Q - Rapport Therapeutics, Inc. (0002012593) (Filer)

    8/7/25 7:30:23 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rapport Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Rapport Therapeutics, Inc. (0002012593) (Filer)

    8/7/25 7:15:37 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Rapport Therapeutics Inc.

    EFFECT - Rapport Therapeutics, Inc. (0002012593) (Filer)

    7/10/25 12:15:24 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Ignelzi Troy A. bought $100,988 worth of shares (10,000 units at $10.10) (SEC Form 4)

    4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

    3/13/25 5:13:57 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Young Wendy B. bought $61,250 worth of shares (6,000 units at $10.21) (SEC Form 4)

    4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

    3/13/25 5:00:03 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Healy James bought $1,079,575 worth of shares (44,032 units at $24.52) (SEC Form 4)

    4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

    7/3/24 8:04:04 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPP
    Leadership Updates

    Live Leadership Updates

    View All

    Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors

    Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Raymond Sanchez, M.D., to its Board of Directors, effective August 12, 2025. Dr. Sanchez is a highly accomplished executive with a strong background in medicine and over 20 years of strategic experience in the life sciences industries. "We are delighted to welcome Ray to our Board of Directors as we continue advancing multiple clinical-stage precision psychiatry programs," said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. "Ray brings an impress

    8/13/25 8:03:00 AM ET
    $ANRO
    $CERE
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

    Results of positron emission tomography (PET) trial and second multiple ascending dose (MAD-2) trial support RAP-219's transformative potential for epilepsy and other central nervous system (CNS) disorders Continued momentum in the Phase 2a trial of RAP-219 in patients with refractory focal epilepsy, with topline results expected in the third quarter of 2025Expect to initiate a Phase 2a trial in patients with bipolar mania in the third quarter of 2025, with topline results expected in the first half of 2027  Appointed recognized translational and clinical drug development leader, Jeffrey Sevigny, M.D., as chief medical officer  Ended the year with $305.3 million in cash, cash equivalents, an

    3/11/25 7:00:00 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development

    BOSTON and SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients suffering from central nervous system (CNS) disorders, today announced the appointment of Dr. Jeffrey Sevigny as chief medical officer (CMO), effective immediately. A physician-scientist with more than 15 years of leadership in translational and clinical drug development, Dr. Sevigny has spearheaded groundbreaking research across neuroscience and rare diseases. His experience spans the full spectrum of development, from discovery to late-stage clinical trials an

    3/3/25 7:00:00 AM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Rapport Therapeutics Inc.

    SC 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)

    11/14/24 5:13:31 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Rapport Therapeutics Inc.

    SC 13G/A - Rapport Therapeutics, Inc. (0002012593) (Subject)

    11/14/24 3:11:15 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Rapport Therapeutics Inc.

    SC 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)

    11/13/24 12:26:41 PM ET
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care